What is the efficacy of Micronized Purified Flavonoid Fraction (MPFF) in treatment of Chronic Venous Oedema?

The purpose of the study was to assess efficacy and safety of using in real clinical practice Micronized Purified Flavonoid Fraction (MPFF) in patients with Chronic Venous Oedema.

According to a meta-analysis, the Micronized Purified Flavonoid Fraction (MPFF) turned out to possess better parameters in relation to therapy of Chronic Venous Oedema as compared with other phlebotropic agents.

Therefore, it appears logical to predominantly use the Micronized Purified Flavonoid Fraction (MPFF) in real clinical practice in patients with the CEAP C3 clinical class, which was registered in the study. An important result was also the fact that within the specified terms of follow up surgical intervention demonstrated no significant advantage over conservative therapy alone in treatment of chronic venous oedema. Moreover, conservative treatment in the form of a combination of compression and phlebotropic therapy demonstrated a dynamic decrease in the volume of the affected extremity with a probable transition of the CEAP C3 clinical class to C2.

The Micronized Purified Flavonoid Fraction (MPFF) at a standard daily dose of 1000 mg in a combination with compression therapy irrespective of the surgical intervention performed resulted in a significant dynamic decrease in the volume of the calf in patients with chronic diseases of lower limb veins. An anti-oedematous effect of the Micronized Purified Flavonoid Fraction (MPFF) in a combination with compression manifests itself during the entire period of treatment.

To know more : Click here

V Iu Bogachev, Angiol Sosud Khir.2020;26²:86-94. doi: 10.33529/ANGI02020211.